FOXP3 and viral infectious disease: TMEV-infected mice treated with ex vivo-generated FoxP3+ Tregs at an early stage of viral infection worsened the clinical signs, whereas the mice treated with the Tregs at a later stage decreased immune cell recruitment in the CNS [167].